ArticlePediatric research2026
Safety, tolerability, and gastrointestinal effect of a Bifidobacterium-based synergistic synbiotic in infants and toddlers.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBifidobacterium are critical components of the infant gut microbiome, yet most infants in developed countries are deficient.
methodsThe ARTEMIS trial is the first clinical study in the United States to evaluate a synergistic synbiotic supplement in infants. It enrolled 114 participants in a randomized, double-blind, placebo-controlled study conducted to evaluate the safety, tolerability, and gastrointestinal colonization of the supplement in infants (n = 58) and toddlers (n = 56). The synbiotic contains four proprietary strains of Bifidobacterium, four complementary human milk oligosaccharides and vitamin D.
resultsSafety and tolerability were assessed, with no statistically significant differences in adverse events or gastrointestinal symptom burden relative to placebo. The administered Bifidobacterium strains were significantly more prevalent and abundant in the synbiotic group. After four weeks of dosing, at least one administered strain was detected in 72% of infants (2-12 months) and 67% of toddlers (12-24 months). Synbiotic supplementation was associated with a significant increase in Bifidobacterium infantis abundance at the species level and human milk oligosaccharide utilization genes. Strains persisted through the two-week washout period, supporting intestinal colonization beyond active supplementation unlike other transient probiotics like Lactobacillus.
conclusionsThis synbiotic was safe, well tolerated, and achieved sustained Bifidobacterium colonization in infants and toddlers. IMPACT: The ARTEMIS trial is the first U.S. clinical study to evaluate a synergistic synbiotic in infants combining multiple Bifidobacterium strains with human milk oligosaccharides (HMOs). Safety and tolerability were evaluated in infants and toddlers, with no statistically significant differences in adverse events or gastrointestinal tolerance compared with placebo. Infants and toddlers receiving the synbiotic showed significantly greater prevalence and abundance of the administered strains, demonstrating successful gut colonization and shifts in overall Bifidobacterium populations, along with increased abundance of HMO-utilization genes. In toddlers, synbiotic supplementation was associated with a significant improvement in sleep relative to placebo.
Identifiers
42587033What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.